Making Real World Evidence Less 'Messy' To Help With Drug Pricing

 
• By Brenda Sandburg

The Medicines Company's inclisirin CV trial is 100-fold cheaper with digitized records, while Lilly is still hunting for a good HBA1C dataset, and Merck worries about "idiosyncratic" data.

FTI real world evidence Panel
Mark Nagy, Eli Lilly; Susan Shiff, Merck; Clive Meanwell, The Medicines Co. • Source: Photo by Brenda Sandburg

More from Pricing Debate

More from Market Access